| -0.265 / -4.49%|
Novavax, Inc. is a clinical-stage biopharmaceutical company, which engages in development of novel recombinant vaccines to address a broad range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles and recombinant nanoparticle vaccines. Its product pipeline targets a variety of infectious diseases and currently has completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and Respiratory Syncytial Virus. The company is committed to using its technology platform to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals Ltd. of India, LG Life Sciences Ltd. of Korea and PATH. Novavax was founded in 1987 and is headquartered in Rockville, MD.
|Stanley C. Erck||President, Chief Executive Officer & Director|
|Barclay A. Phillips||Chief Financial Officer, Treasurer & SVP|
|Gregory M. Glenn||Chief Medical Officer & Senior Vice President|
|Louis F. Fries||Chief Medical Officer & Vice President|
|D. Nigel Thomas||Vice President-Clinical Operations|